BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35058580)

  • 1. Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT.
    Kane N; Romero T; Diaz-Perez S; Rettig MB; Steinberg ML; Kishan AU; Schaue D; Reiter RE; Knudsen BS; Nickols NG
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):207-209. PubMed ID: 35058580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells.
    Nickols NG; Ganapathy E; Nguyen C; Kane N; Lin L; Diaz-Perez S; Nazarian R; Mathis C; Felix C; Basehart V; Zomorodian N; Kwak J; Kishan AU; King CR; Kupelian PA; Rettig MB; Steinberg ML; Cao M; Knudsen BS; Chu FI; Romero T; Elashoff D; Reiter RE; Schaue D
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):135-139. PubMed ID: 32647353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer.
    Hammer L; Jiang R; Hearn J; Lashbrook J; Mitchell A; Daignault-Newton S; Dess RT; Jackson WC; Reichert Z; Alumkal JJ; Kaffenberger S; George A; Montgomery J; Salami SS; Morgan TM; Miller D; Wittman D; Hollenbeck B; Mehra R; Davenport MS; Sun Y; Schipper M; Palapattu G; Spratt DE
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):132-141. PubMed ID: 35878714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences.
    Ehret F; Hofmann T; Fürweger C; Kufeld M; Staehler M; Muacevic A; Haidenberger A
    BJU Int; 2023 Jan; 131(1):101-108. PubMed ID: 36114771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Ablative Radiation Therapy in 3 Fractions Induces a Favorable Systemic Immune Cell Profiling in Prostate Cancer Patients.
    Palermo B; Bottero M; Panetta M; Faiella A; Sperduti I; Masi S; Frisullo G; Foddai ML; Cordone I; Nisticò P; Sanguineti G
    Oncoimmunology; 2023; 12(1):2174721. PubMed ID: 36798427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.
    Katz A; Ferrer M; Suárez JF;
    Radiat Oncol; 2012 Nov; 7():194. PubMed ID: 23164305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
    Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
    JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer.
    Parikh NR; Kishan AU; Kane N; Diaz-Perez S; Ganapathy E; Nazarian R; Felix C; Mathis C; Bradley M; Sachdeva A; Wyatt B; Basehart V; Zomorodian N; Lin L; King CR; Kupelian PA; Rettig MB; Steinberg ML; Cao M; Knudsen BS; Elashoff D; Schaue D; Reiter RE; Nickols NG
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):930-935. PubMed ID: 32562839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial.
    Greco C; Pares O; Pimentel N; Louro V; Santiago I; Vieira S; Stroom J; Mateus D; Soares A; Marques J; Freitas E; Coelho G; Seixas M; Lopez-Beltran A; Fuks Z
    JAMA Oncol; 2021 May; 7(5):700-708. PubMed ID: 33704378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.
    Jiang P; Krockenberger K; Vonthein R; Tereszczuk J; Schreiber A; Liebau S; Huttenlocher S; Imhoff D; Balermpas P; Keller C; Dellas K; Baumann R; Rödel C; Hildebrandt G; Jünemann KP; Merseburger AS; Katz A; Ziegler A; Blanck O; Dunst J
    Radiat Oncol; 2017 Aug; 12(1):138. PubMed ID: 28821268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
    Ma TM; Ballas LK; Wilhalme H; Sachdeva A; Chong N; Sharma S; Yang T; Basehart V; Reiter RE; Saigal C; Chamie K; Litwin MS; Rettig MB; Nickols NG; Yoon SM; Smith L; Gao Y; Steinberg ML; Cao M; Kishan AU
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):142-152. PubMed ID: 36007724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
    Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
    Leeman JE; Shin KY; Chen YH; Mak RH; Nguyen PL; D'Amico AV; Martin NE
    Cancer; 2023 Oct; 129(19):3044-3052. PubMed ID: 37485697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.
    Zilli T; Scorsetti M; Zwahlen D; Franzese C; Förster R; Giaj-Levra N; Koutsouvelis N; Bertaut A; Zimmermann M; D'Agostino GR; Alongi F; Guckenberger M; Miralbell R
    Radiat Oncol; 2018 Sep; 13(1):166. PubMed ID: 30180867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
    Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
    Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.